NDAINTRAVENOUSINJECTABLE
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
PARAPLATIN (carboplatin) by Engine Biosciences is clinical pharmacology carboplatin, like cisplatin, produces predominantly inter strand dna cross-links rather than dna-protein cross-links. First approved in 2003.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Carboplatin, like cisplatin, produces predominantly inter strand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, whichis thought to produce the active species, occurs at a slower rate than in…
Worked on PARAPLATIN at Engine Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.